277
Views
8
CrossRef citations to date
0
Altmetric
Original Article

Is ovarian volume a good predictor to determine metabolic syndrome development in polycystic ovary patients

ORCID Icon, , , , &

References

  • Anon. 2004. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction 19:41–47.
  • Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. 2005. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism 90:1929–1935.
  • Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. 2006. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. The Journal of Clinical Endocrinology & Metabolism 91:4237–4245.
  • Behboudi-Gandevani S, Amiri M, Bidhendi Yarandi R, Noroozzadeh M, Farahmand M, Rostami Dovom M, et al. 2018. The risk of metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Clinical Endocrinology(Oxford) 88:169–184.
  • Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. 2016. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction 31:2841–2855.
  • Bozdag G, Salman MC, Mumusoglu S, Yapici Z, Gunalp S. 2012. Is ovarian volume estimation reliable when compared with true volume? American Journal of Obstetrics & Gynecology 206:44.e1–44.
  • Carmina E, Napoli N, Longo RA, Rini GB, Lobo RA. 2006. Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS. European Journal of Endocrinology 154:141–145.
  • Clark NM, Podolski AJ, Brooks ED, Chizen DR, Pierson RA, Lehotay DC, et al. 2014. Prevalence of polycystic ovary syndrome phenotypes using updated criteria for polycystic ovarian morphology: an assessment of over 100 consecutive women self-reporting features of polycystic ovary syndrome. Reproductive Sciences 21:1034–1043.
  • De Cicco S, Immediata V, Romualdi D, Policola C, Tropea A, Di Florio C, et al. 2017. Myoinositol combined with alpha-lipoic acid may improve the clinical and endocrine features of polycystic ovary syndrome through an insulin-independent action. Gynecological Endocrinology journal 33:698–701.
  • Delitala AP, Capobianco G, Delitala G, Cherchi PL, Dessole S. 2017. Polycystic ovary syndrome, adipose tissue and metabolic syndrome. Archives of Gynecology and Obstetrics 296:405–419.
  • Deugarte CM, Bartolucci AA, Azziz R. 2005. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertility and Sterility 83:1454–1460.
  • Diamanti-Kandarakis E, Dunaif A. 2012. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocrine Reviews 33:981–1030.
  • Dokras A, Bochner M, Hollinrake E, Markham S, Vanvoorhis B, Jagasia DH. 2005. Screening women with polycystic ovary syndrome for metabolic syndrome. Obstetrics & Gynecology 106:131–137.
  • Duleba AJ, Spaczynski RZ, Olive DL. 1998. Insulin and insulin-like growth factor I stimulate the proliferation of human ovarian theca-interstitial cells. Fertility and Sterility 69:335–340.
  • Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN. 2006. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism 91:48–53.
  • Ford ES, Giles WH, Mokdad AH. 2004. Increasing prevalence of the metabolic syndrome among U.S. Adults. Diabetes Care 27:2444–2449.
  • Fulghesu AM, Angioni S, Frau E, Belosi C, Apa R, Mioni R, et al. 2007. Ultrasound in polycystic ovary syndrome–the measuring of ovarian stroma and relationship with circulating androgens: results of a multicentric study. Human Reproduction 22:2501–2508.
  • Genazzani AD, Battaglia C, Malavasi B, Strucchi C, Tortolani F, Gamba O. 2004. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertility and Sterility 81:114–119.
  • Gharakhani M, Neghab N, Farimani M. 2011. Is reducing ovarian volume in polycystic ovarian syndrome patients after administration of metformin associated with improving cardiovascular risk factors? International Journal of Fertility & Sterility 5:90–95.
  • Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. 2011. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nature Reviews Endocrinology 7:219–231.
  • Hong SH, Sung YA, Hong YS, Jeong K, Chung H, Lee H. 2017. Polycystic ovary morphology is associated with insulin resistance in women with polycystic ovary syndrome. Clinical Endocrinology(Oxford) 87:375–380.
  • Kollmann M, Martins WP, Lima ML, Craciunas L, Nastri CO, Richardson A, et al. 2016. Strategies for improving outcome of assisted reproduction in women with polycystic ovary syndrome: systematic review and meta-analysis. Ultrasound in Obstetrics & Gynecology 48:709–718.
  • Lim SS, Norman RJ, Davies MJ, Moran LJ. 2013. The effect of obesity on polycystic ovary syndrome: a systematic review and meta-analysis. Obesity Reviews 14:95–109.
  • Lujan ME, Jarrett BY, Brooks ED, Reines JK, Peppin AK, Muhn N, et al. 2013. Updated ultrasound criteria for polycystic ovary syndrome: reliable thresholds for elevated follicle population and ovarian volume. Human Reproduction 28:1361–1368.
  • Reid SP, Kao CN, Pasch L, Shinkai K, Cedars MI, Huddleston HG. 2017. Ovarian morphology is associated with insulin resistance in women with polycystic ovary syndrome: a cross sectional study. Fertility Research and Practice 3:8.
  • Sung YA, Oh JY, Chung H, Lee H. 2014. Hyperandrogenemia is implicated in both the metabolic and reproductive morbidities of polycystic ovary syndrome. Fertility and Sterility 101:840–845.
  • Techatraisak K, Wongmeerit K, Dangrat C, Wongwananuruk T, Indhavivadhana S. 2016. Measures of body adiposity and visceral adiposity index as predictors of metabolic syndrome among Thai women with PCOS. Gynecological Endocrinology 32:276–280.
  • Unfer V, Nestler JE, Kamenov ZA, Prapas N, Facchinetti F. 2016. Effects of Inositol(s) in women with PCOS: a systematic review of randomized controlled trials. International Journal of Endocrinology 2016:1849162.
  • Vural B, Caliskan E, Turkoz E, Kilic T, Demirci A. 2005. Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome. Human Reproduction 20:2409–2413.
  • Zaidi J, Jurkovic D, Campbell S, Okokon E, Tan SL. 1995. Circadian variation in uterine artery blood flow indices during the follicular phase of the menstrual cycle. Ultrasound in Obstetrics & Gynecology 5:406–410.
  • Zeyneloglu HB, Haydardedeoglu B, Bagis T, Kilicdag E. 2004. Metformin decreases ovarian volume in lean patients with polycystic ovary syndrome (PCOS). Fertility and Sterility 82:S301.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.